SCYNEXIS.COM: Keyword Density Checker

Total words: 1350 | 2-word phrases: 349 | 3-word phrases: 384 | 4-word phrases: 394

PAGE INFO

Title	Try to keep the title under 60 characters (20 characters) Home Page - Scynexis
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	No H1 tag on the page (0 characters)

#	Keyword	Frequency	Density
1	read more	10	2.87%
2	learn more	7	2.01%
3	scynexis to	6	1.72%
4	infectious diseases	4	1.15%
5	in the	4	1.15%
6	to participate	3	0.86%
7	scy247 at	3	0.86%
8	corporate update	3	0.86%
9	participate in	3	0.86%
10	financial results and	3	0.86%
11	the fight	3	0.86%
12	scynexis reports	3	0.86%
13	results and provides	3	0.86%
14	lifethreatening infections	3	0.86%
15	second generation	3	0.86%
16	on second	3	0.86%
17	data on	3	0.86%
18	preclinical data	3	0.86%
19	generation fungerp	3	0.86%
20	make a	2	0.57%

#	Keyword	Frequency	Density
1	to participate in	3	0.78%
2	financial results and provides	3	0.78%
3	scynexis to participate	3	0.78%
4	preclinical data on	3	0.78%
5	data on second	3	0.78%
6	second generation fungerp	3	0.78%
7	on second generation	3	0.78%
8	2024 financial results and	2	0.52%
9	quarter 2024 financial	2	0.52%
10	scynexis to present	2	0.52%
11	scy247 at the	2	0.52%
12	to present preclinical	2	0.52%
13	the fight against	2	0.52%
14	present preclinical data	2	0.52%
15	in the fight	2	0.52%
16	healthcare virtual summit	1	0.26%
17	h c wainwright	1	0.26%
18	participate in the	1	0.26%
19	in the 2024	1	0.26%
20	the 2024 maxim	1	0.26%
21	2024 maxim healthcare	1	0.26%
22	maxim healthcare virtual	1	0.26%
23	opportunities and more?	1	0.26%
24	scy247 at idweek	1	0.26%
25	more about our	1	0.26%
26	about our products	1	0.26%
27	our products partnership	1	0.26%
28	learning more about	1	0.26%
29	in h c	1	0.26%
30	participate in h	1	0.26%

#	Keyword	Frequency	Density
1	data on second generation	3	0.76%
2	on second generation fungerp	3	0.76%
3	preclinical data on second	3	0.76%
4	scynexis to participate in	3	0.76%
5	quarter 2024 financial results and	2	0.51%
6	present preclinical data on	2	0.51%
7	to present preclinical data	2	0.51%
8	scynexis to present preclinical	2	0.51%
9	2024 financial results and provides	2	0.51%
10	in the 2024 maxim	1	0.25%
11	more about our products	1	0.25%
12	learning more about our	1	0.25%
13	in learning more about	1	0.25%
14	interested in learning more	1	0.25%
15	to participate in the	1	0.25%
16	participate in the 2024	1	0.25%
17	purposes of website accessibility	1	0.25%
18	the 2024 maxim healthcare	1	0.25%
19	2024 maxim healthcare virtual	1	0.25%
20	has the power to	1	0.25%
21	maxim healthcare virtual summit	1	0.25%
22	guggenheim’s 6th annual biotechnology	1	0.25%
23	in guggenheim’s 6th annual	1	0.25%
24	participate in guggenheim’s 6th	1	0.25%
25	to participate in guggenheim’s	1	0.25%
26	about our products partnership	1	0.25%
27	breakthroughs has the power	1	0.25%
28	2023 financial results and provides	1	0.25%
29	options and often deadly	1	0.25%
30	increase of antifungalresistant pathogens	1	0.25%
31	of antifungalresistant pathogens is	1	0.25%
32	antifungalresistant pathogens is reported	1	0.25%
33	pathogens is reported globally	1	0.25%
34	people are on a	1	0.25%
35	our people are on	1	0.25%
36	considering the limited treatment	1	0.25%
37	the limited treatment options	1	0.25%
38	limited treatment options and	1	0.25%
39	treatment options and often	1	0.25%
40	and often deadly outcomes	1	0.25%